<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686320</url>
  </required_header>
  <id_info>
    <org_study_id>NI-2015</org_study_id>
    <nct_id>NCT02686320</nct_id>
  </id_info>
  <brief_title>Prospective Study of Patients With Rheumatoid Arthritis After the Age of 65</brief_title>
  <acronym>PRESAGE</acronym>
  <official_title>Prospective Study of Evolution of Rheumatoid Arthritis After 65 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is associated with a higher prevalence of infections, malignancies,
      osteoporotic fractures and cardiovascular diseases. Few data are available regarding the
      prevalence and severity of these comorbidities in elderly RA patients. The purpose of this
      study is to determine the effect of age on prevalence and severity of comorbidities in RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevalence of rheumatoid arthritis (RA) in elderly is increasing because of the increasing
      life expectancy. RA is associated with a higher prevalence of infections, malignancies,
      osteoporotic fractures and cardiovascular diseases. The purpose of this study is to determine
      the effect of age on prevalence and severity of comorbidities in RA. This study also aims to
      determine whether age influences disease progression and efficacy and tolerance of
      treatments.

      This study will compare two groups of patients : patients older than 65 years old and
      patients younger than 50 years old, matched for gender and disease duration.

      The first part of the study will be cross-sectional and will aim to compare characteristics
      regarding RA manifestations and comorbidities of the two groups at inclusion.

      Whereas the second part will be prospective to assess the occurrence of comorbidities and the
      efficacy and safety of treatments in these two groups. Patients will be assessed every year
      during 5 years in accordance with usual follow-up of the patients.

      This study could help to better manage elderly RA patients and to modify clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of severe infections</measure>
    <time_frame>5 years</time_frame>
    <description>Occurrence of severe infection requiring hospitalization or varicella-zoster virus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cancers</measure>
    <time_frame>5 years</time_frame>
    <description>Occurrence of solid cancer or hemopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cardiovascular diseases</measure>
    <time_frame>5 years</time_frame>
    <description>Occurrence of myocardial infarction or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of osteoporotic fractures</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS 28)</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate articular activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simple Disease Activity Index (SDAI)</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate clinical articular activity of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate biological articular activity of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of C-reactive protein (CRP)</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate biological articular activity of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of synovitis and/or tenosynovitis at ultrasound of hands</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate articular activity of rheumatoid arthritis at ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessment questionnaire (HAQ) score</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of orthopaedic surgery</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate severity of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of erosions at X-rays (hands and feet)</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate severity of rheumatoid arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of diabetes, arterial hypertension and dyslipidaemia</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate risks factor of cardiovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cataracts</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vaccinations</measure>
    <time_frame>5 years</time_frame>
    <description>Previous influenza vaccination within the previous year and pneumococcal vaccination within the previous 5 years will be searched during medical interview.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis &gt;65 years old</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis &lt;50 years old</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis patients from department A and B of rheumatology in Cochin hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Rheumatoid arthritis according to American College of
             Rheumatology (ACR) /Eular 2010 criteria or American College of Rheumatalogy 1987
             criteria

          -  Age &gt;65 years or patients between 18 and 50 years matched for sex and disease duration
             with the group of elderly patients (control group)

        Exclusion Criteria:

          -  Patients who do not understand rules and implications of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick ALLANORE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique- Hôpitaux de Paris, Cochin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel ELHAI, MD, PhD</last_name>
    <phone>+33 1 58 41 31 72</phone>
    <email>muriel.elhai@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie FAUROUX, Master</last_name>
    <phone>+33 1 58 41 12 13</phone>
    <email>valerie.fauroux@cch.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel ELHAI, MD, PhD</last_name>
      <phone>+33 1 58 41 31 72</phone>
      <email>muriel.elhai@cch.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Soubrier M, Tatar Z, Couderc M, Mathieu S, Dubost JJ. Rheumatoid arthritis in the elderly in the era of tight control. Drugs Aging. 2013 Nov;30(11):863-9. doi: 10.1007/s40266-013-0122-8. Review.</citation>
    <PMID>24105334</PMID>
  </reference>
  <reference>
    <citation>Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Mar;65(3):353-61. doi: 10.1002/acr.21812.</citation>
    <PMID>22833532</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Elderly</keyword>
  <keyword>infections</keyword>
  <keyword>cardio-vascular disease</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

